KA Virtanen, K Hällsten, R Parkkola, T … - Diabetes, 2003 - Am Diabetes Assoc We evaluated the effects of rosiglitazone (4 mg bid) and metformin (1 g bid)
monotherapy for 26 weeks on adipose tissue insulin-stimulated glucose uptake in
patients (n = 41) with type 2 diabetes. Before and after the treatment, ... Cited by 112 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org K Hällsten, KA Virtanen, F Lönnqvist, H … - Diabetes, 2002 - Am Diabetes Assoc Rosiglitazone, a thiazolidinedione, enhances peripheral insulin sensitivity in
patients with type 2 diabetes. Because the synergic action of insulin and
exercise has been shown to be decreased in insulin resistance, the aim of ... Cited by 98 - Related articles - BL Direct - All 6 versions
P Iozzo, K Hallsten, V Oikonen, KA Virtanen, R … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Fasting plasma glucose levels were significantly decreased after
either rosiglitazone (−0.9 ± 0.5 mmol/l) or metformin treatment (−1.1 ±
0.5 mmol/l) in comparison with placebo; only metformin was associated with ... Cited by 36 - Related articles - BL Direct - All 5 versions
DG Carey, GJ Cowin, GJ Galloway, NP Jones, … - Obesity, 2002 - nature.com Results: There was a significant improvement in glycemic control (glycosylated
hemoglobin -0.7 0.7%, p 0.05) and an 86% increase in insulin sensitivity in the
RSG group (glucose-disposal rate change from baseline: 17.5 14.5 mol ... Cited by 130 - Related articles - All 3 versions
Y Miyazaki, L Glass, C Triplitt, M Matsuda, … - Diabetologia, 2001 - Springer The thiazolidinediones represent a new class of insu- lin sensitizing agents for
the treatment of Type II (non-insulin-dependent) diabetes mellitus. The origi-
nal drug in this class, troglitazone, has been shown to ameliorate insulin ... Cited by 206 - Related articles - BL Direct - All 5 versions
[CITATION] Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in …
TA Jones, M Sautter, LF Van Gaal, NP Jones - Diabetes Obesity and Metabolism, 2003 - interscience.wiley.com Aim: These analyses were undertaken to evaluate the efficacy of the insulin
sensitizer rosiglitazone (RSG) when added to the therapy of obese type 2
diabetes mellitus patients (T2DM) taking near-maximal doses (2.5 g/day) of ... Cited by 83 - Related articles - BL Direct - All 3 versions
MI Freed, R Ratner, SM Marcovina, MM … - The American journal of cardiology, 2002 - Elsevier This study evaluated the effects of rosiglitazone therapy on lipids and the
efficacy and safety of rosiglitazone in combination with atorvastatin in
patients with type 2 diabetes mellitus. Three-hundred thirty-two patients ... Cited by 170 - Related articles - All 5 versions
TP Ciaraldi, APS Kong, NV Chu, DD Kim, S … - Diabetes, 2002 - Am Diabetes Assoc Type 2 diabetic subjects failing glyburide therapy were randomized to receive
additional therapy with either metformin (2,550 mg/day) or troglitazone (600
mg/day) for 3–4 months. Biopsies of subcutaneous abdominal adipose tissue ... Cited by 67 - Related articles - BL Direct - All 4 versions
